Hepatitis C - Screening for HCC in the Post-SVR12 Setting

2018 - Updates

Letter to the editor

Jan 2018

Hepatocellular Carcinoma Screening in Patients Treated for Hepatitis C

SVR Reduced HCC by 71%
from Jules: there never was any doubt that SVR would reduce or eliminate risk for HCC. In this study cirrhosis prior to treatment had a higher HCC risk then for those without cirrhosis, but that is to be expected and merely reinforces how crucial it is to treat HCV as early as possible...
Full Text

Liver cancer incidence after HCV therapy linked to risk factors, not treatment

Direct-acting antiviral treatment for hepatitis C did not correlate with an increased risk for hepatocellular carcinoma in a large cohort study of both treated and untreated patients with or without cirrhosis. Those with incident HCC after DAA treatment had higher risk factors at baseline.

Dec 2016

Healio

The following articles appeared in the December print edition of HCV NEXT, published online at Healio.

Table of Contents
5 Questions
A Conversation With Zobair M. Younossi, MD, MPH

Cover Story
Screening for HCC in the Post-SVR12 Setting

Editorial
HCV Testing Needs Expansion Beyond Baby Boomers

The Take Home
The Liver Meeting 2016

Infectious Disease Week 2016

The Liver Meeting 2016: Beyond HCV

Trend Watch
CMS: Harvoni Outpaces Other Drugs in Total Spending
Canadian Patients With HCV Often Restricted From DAA Treatment

Begin here.....